Literature DB >> 12974735

Psychological consequences and predictors of adverse events in the first 5 years after predictive testing for Huntington's disease.

E W Almqvist1, R R Brinkman, S Wiggins, M R Hayden.   

Abstract

The promise of genetic medicine is to provide information, based on genotype, to persons not yet sick about their risk of future illness. However, little is known of the long-term psychological effects for asymptomatic persons learning their risk of having a serious disease. Predictive genetic testing for Huntington's disease (HD) has been offered for the longest time for any disease. In the present study, the psychological consequences of predictive testing were assessed prospectively in individuals at risk for HD during seven visits over 5 years. Questionnaires of standard measures of psychological distress (the General Severity Index of the Symptom Check List-90-Revised), depression (the Beck Depression Inventory), and general well-being (the General Well-Being Scale) were administered to the participants. A significant reduction in psychological distress was observed for both result groups throughout 2 years (p < 0.001) and at 5 years (p = 0.002). Despite the overall improvement of the psychological well-being, 6.9% (14 of 202) of the participants experienced an adverse event during the first 2 years after predictive testing that was clinically significant. The frequency of all defined adverse events in the participants was 21.8%, with higher frequency in the increased risk group (p = 0.03) and most occurring within 12 months of receiving results.

Entities:  

Mesh:

Year:  2003        PMID: 12974735     DOI: 10.1034/j.1399-0004.2003.00157.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  33 in total

1.  Genetics Health Professionals' Views on Quality of Genetic Counseling Service Provision for Presymptomatic Testing in Late-Onset Neurological Diseases in Portugal: Core Components, Specific Challenges and the Need for Assessment Tools.

Authors:  M Paneque; Á Mendes; L Guimarães; J Sequeiros; H Skirton
Journal:  J Genet Couns       Date:  2014-11-04       Impact factor: 2.537

Review 2.  Methodology in longitudinal studies on psychological effects of predictive DNA testing: a review.

Authors:  R Timman; T Stijnen; A Tibben
Journal:  J Med Genet       Date:  2004-07       Impact factor: 6.318

3.  Factors associated with experiences of genetic discrimination among individuals at risk for Huntington disease.

Authors:  Yvonne Bombard; JoAnne Palin; Jan M Friedman; Gerry Veenstra; Susan Creighton; Jane S Paulsen; Joan L Bottorff; Michael R Hayden
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-11-10       Impact factor: 3.568

Review 4.  Emerging empirical evidence on the ethics of schizophrenia research.

Authors:  Laura B Dunn; Philip J Candilis; Laura Weiss Roberts
Journal:  Schizophr Bull       Date:  2005-10-19       Impact factor: 9.306

5.  Depression and suicidal ideation after predictive testing for Huntington's disease: a two-year follow-up study.

Authors:  Maria U Larsson; Mary A Luszcz; The-Hung Bui; Tarja-Brita Robins Wahlin
Journal:  J Genet Couns       Date:  2006-10       Impact factor: 2.537

Review 6.  Why tell asymptomatic children of the risk of an adult-onset disease in the family but not test them for it?

Authors:  P J Malpas
Journal:  J Med Ethics       Date:  2006-11       Impact factor: 2.903

7.  More appreciation of life or regretting the test? Experiences of living as a mutation carrier of Huntington's disease.

Authors:  Anette Hagberg; The-Hung Bui; Elisabeth Winnberg
Journal:  J Genet Couns       Date:  2010-09-28       Impact factor: 2.537

8.  DNA: where to now?

Authors:  John Beilby
Journal:  Clin Biochem Rev       Date:  2007-05

9.  What to Do with a Second Chance in Life? Long-Term Experiences of Non-carriers of Huntington's Disease.

Authors:  Elisabeth Winnberg; Ulrika Winnberg; Lilian Pohlkamp; Anette Hagberg
Journal:  J Genet Couns       Date:  2018-04-07       Impact factor: 2.537

10.  Grading quality of evidence and strength of recommendations for diagnostic tests and strategies.

Authors:  Holger J Schünemann; A Holger J Schünemann; Andrew D Oxman; Jan Brozek; Paul Glasziou; Roman Jaeschke; Gunn E Vist; John W Williams; Regina Kunz; Jonathan Craig; Victor M Montori; Patrick Bossuyt; Gordon H Guyatt
Journal:  BMJ       Date:  2008-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.